Inceptua announces global license agreement for the commercialization of JETREA®
"Having been established for more than 20 years, we have a solid infrastructure with industry-leading capabilities and operations across North America, Europe, and Asia".
JETREA® was launched in early 2013, and over 35,000 patients have been treated with the product to-date with real world clinical data confirming that the drug is a safe and effective early treatment for a well identified group of patients suffering from symptomatic vitreomacular adhesion or vitreomacular traction.
The EU Marketing Authorization and global distribution rights will be transferred to the Inceptua Group during 2020, and will vary by region. In Europe, the Marketing Authorization transfer is expected to be completed by Summer 2020.
Inceptua is a pharmaceutical company and service partner spanning throughout the product lifecycle – from clinical trial comparator sourcing, packaging, labelling, and distribution solutions, through early access and unlicensed medicines programs to licensing and commercialization of products.
Inceptua partners with life science companies of all sizes, drawing on over 20 years of industry experience:
- Inceptua Pharma commercializes and market orphan and specialty care products and have the expertise and capabilities to supply unlicensed medicines globally
- Inceptua Services supports pharma and biotech companies with global clinical trial comparator sourcing, packaging and labelling solutions, pre-approval and medicines access programs and consulting
Inceptua has global operations with local offices across Europe, USA, and Asia.